Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLPG0187 · 2 trials · 2 indications
Patients will be monitored for cardiovascular safety (ECG) and adverse events, and blood- and urine-samples taken before and at fixed timepoints after a one-hour infusion of GLPG0187; if patients tolerate the treatment well, procedures will be repeated before and at fixed timepoints after the start of a three-week continuous infusion patients. Through monitoring and analysis of the blood- and urine-samples, it will be established whether the study medication would have any negative effects on the patient's general condition. Results will indicate whether DLT has occurred.
| Arm | Type | Description |
|---|---|---|
| GLPG0187 | EXPERIMENTAL | GLPG0187 for infusion |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GLPG0187 | DRUG | continuous IV infusion |
| Placebo | DRUG | Matching subcutaneous or oral placebo |
Inclusion Criteria: * Pathologically confirmed diagnosis of advanced, recurrent, or metastatic cancer who are refractory to standard therapy or for whom no standard therapy exist. * Age of 18 years or older. * Measurable (according to RECIST 1.1) and evaluable disease as determined by the Investiga...